In gastric cancer, the preclinical study conducted by Yamashita et al. showed that trastuzumab can upregulate PD-L1 in HER2-amplified gastric cancer cells by interacting with NK cells through the secretion of IFN-γ [91]. The gene discussed is ERBB2; the disease is gastric cancer.